KLK3 and posterior cortical atrophy: Until PSA’s isolation in 1979 by Dr. Ming Chu’s research group [1,2] and, later, the development of an ELISA immunoassay that could be used for its blood detection [3], one of the only biomarkers available to evaluate PCa, the prostatic acid phosphatase, had the limitation of only becoming elevated in men with metastatic bone disease [4].